BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260924T130000
DTEND;TZID=America/New_York:20260924T140000
DTSTAMP:20260924T004513
CREATED:20260904T191958Z
LAST-MODIFIED:20260904T200233Z
UID:73684-1790254800-1790258400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Genentech - Treatments on the Horizon: Research into the Management of Hemophlia A and von Willebrand Disease
DESCRIPTION:Date: Thursday\, September 24th\, 2026\nTime: 1:00pm – 2:00pm ET \n \n \nWEBINAR TOPIC:\nTreatments on the Horizon: Research into the Management of Hemophlia A and von Willebrand Disease \nOBJECTIVES: \n\nProvide an update on Genentech pipeline and treatments under investigation for rare blood disorders\nReview investigational agents and enrolling trials for hemophilia A\, highlighting NTX007 and SPK-8011QQ gene therapy\nDiscuss the rationale and enrolling trials investigating emicizumab in Type 3 von Willebrand Disease\n\n\nAUDIENCE:\nAll HTC Staff \nSPEAKER:\nEunice Tzeng\, PharmD\nPrincipal Medical Science Director – Rare Blood Disorders\, US Medical\nGenentech\, a Member of the Roche Group\n \nEunice is a Principal Medical Science Director on the Rare Blood Disorders team at Genentech\, where she has served for the past 10 years. Prior to joining Genentech\, she spent over a decade as a clinical pharmacist at UCSF Medical Center. Eunice earned her undergraduate degree from UC Berkeley and her Doctor of Pharmacy from UCSF School of Pharmacy. A rare San Francisco native\, she still calls the city home today.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-genentech-treatments-on-the-horizon-research-into-the-management-of-hemophlia-a-and-von-willebrand-disease/
CATEGORIES:Members Only
END:VEVENT
END:VCALENDAR